(AADI) Aadi Bioscience - Ratings and Ratios

Aadi Bioscience, Inc. (NASDAQ:AADI) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of precision therapies targeting genetically defined cancers with mTOR pathway alterations. The companys lead product, FYARRO, is an FDA-approved sirolimus protein-bound particles for injectable suspension designed for the treatment of adult patients with advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa). Aadi is also investigating the efficacy of FYARRO in other cancers characterized by specific genomic alterations that activate the mTOR pathway, such as TSC1 or TSC2 mutations. Established in 2007, the company is headquartered in Pacific Palisades, California.

From a technical standpoint, AADIs stock is trading below its 20-day and 50-day moving averages, which are currently at 2.64 and 2.90, respectively. The stock is slightly above its 200-day moving average of 2.11, indicating potential support at this level. The average trading volume over the past 20 days is 95,786 shares, with an average true range (ATR) of 0.18, suggesting moderate volatility.

Fundamentally, Aadi Bioscience has a market capitalization of approximately $63.47 million, with a price-to-book ratio of 0.92, indicating that the stock is trading below its book value. The company currently reports a negative return on equity (RoE) of -89.57%, reflecting significant losses in its operations. The price-to-sales ratio stands at 2.53, which is relatively moderate compared to industry peers.

Looking ahead, AADIs stock price is expected to remain under pressure in the near term, given its position below key moving averages and negative earnings trends. However, the companys focus on precision oncology and its approved product, FYARRO, position it as a potential player in the targeted cancer therapy space. The 3-month forecast suggests that AADI may face resistance at the $2.90 level, with support near $2.11. The stocks trajectory will likely depend on clinical trial outcomes and the companys ability to achieve profitability.